CD40 Agonists & CD40/Ligand Antagonists Pipeline Market Review 2024: Drug Code/INN, Target(s)/MoA, Class of Compound, Territory of Main Competitor, Indication(s) & R&D Stage
October 24, 2024 10:14 ET
|
Research and Markets
Dublin, Oct. 24, 2024 (GLOBE NEWSWIRE) -- The "CD40 Agonists & CD40/L Antagonists Pipeline Review" report has been added to ResearchAndMarkets.com's offering. This product provides basic...
Acute Graft-Versus-Host Disease Pipeline Research 2024 Featuring MaaT Pharma, Medac, CSL Behring, Humanigen, Ironwood Pharmaceuticals, ReAlta Life Sciences, Roche, and Incyte
June 26, 2024 09:34 ET
|
Research and Markets
Dublin, June 26, 2024 (GLOBE NEWSWIRE) -- The "Acute Graft-Versus-Host Disease - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "Acute...
Graft versus Host Disease (GvHD) Pipeline Insights Report, 2024: Reveals 60+ Companies Engaged in Advancing 65+ Pipeline Drugs
May 28, 2024 06:38 ET
|
Research and Markets
Dublin, May 28, 2024 (GLOBE NEWSWIRE) -- The "Graft versus host disease - Pipeline Insight, 2024" report has been added to ResearchAndMarkets.com's offering. This report offers an in-depth look...
Immunotherapy Advancements: CD40 Agonist and Antagonist Research Fuels Oncology and Autoimmunity Treatment Innovations
December 14, 2023 05:33 ET
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "CD40 Agonists & CD40/L Antagonists Pipeline Review" report has been added to ResearchAndMarkets.com's offering. The global scientific community...
Lerapolturev (Formerly Known as PVSRIPO) + Pembrolizumab for Glioblastoma Multiforme (GBM): Emerging Drug Insights and Market Forecast Report, 2019-2023 & 2023-2032
November 22, 2023 08:58 ET
|
Research and Markets
Dublin, Nov. 22, 2023 (GLOBE NEWSWIRE) -- The "Lerapolturev + Pembrolizumab Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...